CloneID: 1G3
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated by immunizing BALB/c mice with a recombinant c-terminus galectin-9 (residues 191 to 355 of the galectin-9 long isoform).
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: O00182
Specificity Statement: This antibody is specific for human Gal-9 but exhibits cross-binding of murine Gal-9.
Application Notes (Clone): The binding and binding specificity of the original format of this antibody to c-terminus Gal-9 were assessed via ELISA. Epitope mapping was also done using ELISA. Furthermore, this antibody was successfully used in WB and IHC assays (Barjon et al., 2012; PMID: 22805533). An scFv-CAR version of this antibody with therapeutic potential was developed and described (US20230295564A1). This antibody was successfully used to neutralize LGALS9 in a study focused on pancreatic neoplastic lesions (Quilbe et al., 2023; PMID: 38098486). This antibody was used in a T lymphocyte proliferation assay, specifically in assessing the immunomodulatory properties of extracellular vesicles (C15SEVs) derived from nasopharyngeal carcinoma and recombinant Galectin-9S. In this assay, the antibody was used to block the impact of C15SEVs and recombinant Galectin-9 on peripheral blood mononuclear cells (Lefebvre et al., 2023; PMID: 38117000).
English
Deutsch
